Clinical trial
Phase II Study With Abraxane, Bevacizumab and Carboplatin in Triple Negative…
NCT00479674 · Duke University, Other · Completed
Key facts
| NCT number | NCT00479674 |
|---|---|
| Title | Phase II Study With Abraxane, Bevacizumab and Carboplatin in Triple Negative Metastatic Breast Cancer |
| Official title | A Phase II Study of Abraxane®, Carboplatin and Bevacizumab in "Triple Negative" (Demonstrating No Expression for Estrogen, Progesterone, or Her2 Receptors) Metastatic Breast Cancer |
| Acronym | ABC |
| Lead sponsor | Duke University, Other |
| Collaborators | Genentech, Inc. Industry Celgene Corporation |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Breast Cancer |
| Intervention type | Drug |
| Interventions | Abraxane, Bevacizumab, Carboplatin |
| Enrollment | 41 |
| Start date | May 1, 2007 |
| Primary completion | Mar 1, 2014 |
| Completion | Mar 1, 2014 |
| First posted | May 28, 2007 |
| Last update posted | Feb 18, 2015 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: